Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
Kyowa Hakko Kirin said on November 28 that it has entered into a license agreement with Ardelyx for exclusive rights to develop and commercialize the US company’s NHE3 inhibitor tenapanor in Japan. Tenapanor, discovered by Ardelyx, is currently being developed…
To read the full story
Related Article
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Kyowa Kirin, Ardelyx Bolster Partnership with Additional Research Deal, US$20 Million Equity Investment
November 27, 2019
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…